Journal: Cerebellum (London, England)

Article Title: Innovative 3D-Image Analysis of Cerebellar Vascularization Highlights Angiogenic Gene Dysregulations in a Murine Model of Apnea of Prematurity

doi: 10.1007/s12311-026-02006-1

Figure Lengend Snippet: Images illustrating the Imaris workflow developed for the vascular network modeling. A–I: Sequential workflow steps allowing the analysis of the cerebellar vascular network of a P4 mouse cerebellum on the Imaris software. From a 3D lightsheet acquisition (A) , the cerebellum is delineated (B) and a mask is created (C) . Within that selected volume, the cerebellar vascularization is segmented (D) , which allows the network visualization (E) and the separation of a deep and a superficial network (F) . Then the threshold of seedpoints is defined (G) , and thanks to the artificial intelligence module (AI), Imaris is able to discriminate “true” (blue) and “false” (red) seedpoints (H) , and “true” (blue) and “false” (red) segments (I) . AI: artificial intelligence; Px: postnatal day x

Article Snippet: One of the typically used software packages for 3D modelling is Imaris from Oxford Instruments Company.

Techniques: Software

Journal: Hla

Article Title: Comparison of Labscan 200 and FlexMap 3D Luminex for Anti‐ HLA Antibodies Monitoring

doi: 10.1111/tan.70731

Figure Lengend Snippet: Qualitative comparison of LABScreen Mix (OLMIX) between LS200 and FM3D. Fusion software assignment (negative/undetermined/positive) was compared for n = 232 patients' sera including negative, false positive and positive profiles. The concordance between LS200 and FM3D acquisitions is represented by the following colours: 100% (white squares) indicated identical assignment between LS200 and FM3D; 50% (pale purple) denoted a slight difference (from positive to undetermined, or undetermined to negative), and 0% (dark blue) portrayed a major discrepancy (from positive to negative). Each square corresponds to the concordance between both Luminex devices for each patient's sera, for either class I (up) or class II (down). Concordance was 89.7% for class I and 96.1% for class II and the weighted Cohen's kappa index was 0.87 for class I and 0.92 for class II. Thirty‐four discordances were observed between both platforms. 23/24 discordances for class I and 9/10 for class II originated from undetermined results on LS200 which became negative on FM3D. Only one sample was discordant for both classes I and II.

Article Snippet: The new Luminex model FlexMap 3D is progressively replacing the previous Luminex generation in HLA laboratories for the detection and identification of anti‐HLA antibodies.

Techniques: Comparison, Software, Luminex

Journal: Hla

Article Title: Comparison of Labscan 200 and FlexMap 3D Luminex for Anti‐ HLA Antibodies Monitoring

doi: 10.1111/tan.70731

Figure Lengend Snippet: Quantitative comparison of LABScreen single antigen classes I and II (OLSAB1/2) between LS200 and FM3D: (a, c) are linear regression for all baseline MFI values obtained for classes I (a) and II (c) between LS200 and FM3D. Dot lines represents line of identity ( y = x ) and point lines depict thresholds (1000 MFI); (b, d) are the Bland–Altman representations of the difference between each measurement, depending on the mean (average) for each bead. The two vertical dot lines correspond to 1000 and 20,000 MFI. The two horizontal dot lines denote the 95% limits of agreement between the two platforms. For note, since baseline MFI obtained with OLSAB1/2 kits may be equal to zero for negative beads, all MFI under 1.0 were artificially increased to 1.0. (a) Regression line for OLSAB1. N = 26 patients' sera and 2522 beads. FM3D MFI ranged from 1.0 to 30,774 (mean = 3791, standard deviation = 7069, first quartile = 2.0, third quartile = 3153), whereas LS200 MFI ranged from 1.0 to 24,361 (mean = 3566, standard deviation = 6481, first quartile = 2.0, third quartile = 3015). Equation line: MFI (FM3D) = 1.09 × MFI (LS200) ( p < 0.0001; R 2 > 0.99). Spearman r s = 0.996, p < 0.0001. (b) Bland–Altman representation for OLSAB1: Difference between LS200 and FM3D MFI, depending on MFI average of both platforms. Ninety‐five percent limits of agreement were −1314; 1766 (horizontal dotted lines). Above 20,000 MFI (vertical dotted lines), the systematic bias depending on MFI increased (21.9 for MFI < 10,000, 489 for 10,000 < MFI < 20,000, 2620 for MFI > 20,000). (c) Regression line for OLSAB2. N = 25 patients' sera and 2375 beads. FM3D MFI ranged from 1.0 to 27,973 (mean = 3159, standard deviation = 6197, first quartile = 6.0, third quartile = 2903), whereas LS200 MFI ranged from 1.0 to 23,990 (mean = 2979, standard deviation = 5765, first quartile = 1.0, third quartile = 2748). Equation line: MFI (FM3D) = 1.07 × MFI (LS200) ( p < 0.0001; R 2 > 0.99). Spearman r s = 0.993, p < 0.0001. (d) Bland–Altman representation for OLSAB2: Difference between LS200 and FM3D MFI depending on MFI average of both platforms. Ninety‐five percent limits of agreement were −892.5; 1251 (horizontal dotted lines). Above 20,000 MFI (vertical dot lines), the systematic bias depending on MFI increased (46.5 for MFI < 10,000, 652 for 10,000 < MFI < 20,000, 2115 for MFI > 20,000).

Article Snippet: The new Luminex model FlexMap 3D is progressively replacing the previous Luminex generation in HLA laboratories for the detection and identification of anti‐HLA antibodies.

Techniques: Comparison, Standard Deviation

Journal: Hla

Article Title: Comparison of Labscan 200 and FlexMap 3D Luminex for Anti‐ HLA Antibodies Monitoring

doi: 10.1111/tan.70731

Figure Lengend Snippet: Quantitative comparison of Lifecodes ID classes I and II (WLSA1/2) between LS200 and FM3D: (a, c) are linear regressions for all MFI raw values obtained for classes I (a) and II (c) between LS200 and FM3D; (b, d) represent the Bland–Altman representations of the difference between each measurement depending on the mean (average) for each bead. The vertical dotted line represents 750 MFI cut‐off. The two horizontal dotted lines represent the 95% limits of agreement between the two platforms. (a) Regression line for WLSA1. N = 62 patients' sera and 5952 beads. FM3D MFI ranged from 42 to 43,434 (mean = 2649, standard deviation = 6465, first quartile = 186, third quartile = 872), whereas LS200 MFI ranged from 25 to 25,145 (mean = 1672, standard deviation = 4003, first quartile = 139, third quartile = 571). Equation line: MFI (FM3D) = 1.61 × MFI (LS200) ( p < 0.0001; R 2 > 0.99). Dot lines denote line of identity ( y = x ). Spearman r s = 0.97, p < 0.0001. (b) Bland–Altman representation for WLSA1: Difference between LS200 and FM3D MFI depending on the MFI average of both platforms. Ninety‐five percent limits of agreement were −3902; 5855 (horizontal dotted lines). The systematic bias dramatically increased with MFI (213 for MFI < 5000, 6300 for 5000 < MFI < 15,000, 10,927 for MFI > 15,000). (c) Regression line for WLSA2. N = 50 patients' sera and 4800 beads. FM3D MFI ranged from 16 to 38,965 (mean = 2133, standard deviation = 5739, first quartile = 91, third quartile = 472), whereas LS200 MFI ranged from 8.0 to 23,416 (mean = 1340, standard deviation = 3555, first quartile = 82, third quartile = 293). Equation line: MFI (FM3D) = 1.61 × MFI (LS200) ( p < 0.0001; R 2 > 0.99). Dot lines denote line of identity ( y = x ). Spearman r s = 0.92, p < 0.0001. (d) Bland–Altman representation for WLSA2: Difference between LS200 and FM3D MFI depending on the MFI average of both platforms. Ninety‐five percent limits of agreement were −3510; 5095 (horizontal dotted lines). The systematic bias dramatically increased with MFI (198 for MFI < 5000, 5614 for 5000 < MFI < 15,000, 11,036 for MFI > 15,000).

Article Snippet: The new Luminex model FlexMap 3D is progressively replacing the previous Luminex generation in HLA laboratories for the detection and identification of anti‐HLA antibodies.

Techniques: Comparison, Standard Deviation

Journal: Hla

Article Title: Comparison of Labscan 200 and FlexMap 3D Luminex for Anti‐ HLA Antibodies Monitoring

doi: 10.1111/tan.70731

Figure Lengend Snippet: Comparison of OLSAB1/2 and WLSA1/2: MFI amplitude and EC50: (a, b) Two monoclonal antibodies pan‐specific for class I, and DR, DP and DQ2 HLA antigens respectively, were serially diluted, and incubated with OLSAB1/2 and WLSA1/2 beads, then analysed with LS200 and FM3D. Boltzmann and least squared regressions gave the same EC50 value, and R 2 > 0.99 for all non‐linear regressions. (a) The four curves represent the Boltzmann non‐linear regression of the mean of all class I beads for each test (all R 2 > 0.99). The highest MFI measured on LS200 and FM3D for OLSAB1 were close (18,346 and 19,404 MFI respectively), as was the case for LS200 WLSA1 maximum MFI (18,652). WLSA1 gave a higher maximum MFI on FM3D (30,585). EC50 were similar between LS200 and FM3D for each supplier: 0.175 and 0.179 μg/mL with OLSAB1, 0.424 and 0.421 μg/mL with WLSA1 respectively. Friedman test (non‐parametric Anova comparison) illustrated that the four curves were significantly different ( p = 0.0003). However, post hoc analysis with Dunn's multiple comparisons test revealed that LS200 and FM3D WLSA1 were significantly different ( p = 0.0006), as was the case for FM3D WLSA1 and LS200 OLSAB1 ( p = 0.003). Interestingly, FM3D WLSA1 and FM3D OLSAB1 were not significantly different ( p = 0.32), and as expected LS200 and FM3D OLSAB1 did not differ ( p = 0.73). Threshold recalculation (bottom of the Boltzmann sigmoid plus 2 or 3 s): 932 and 1285 for LS200 OLSAB1, 927 and 1328 for FM3D OLSAB1, 657 and 958 for LS200 WLSA1, 817 and 1184 for FM3D WLSA1. (b) The four curves represent the Boltzmann non‐linear regression of the mean of all DR, DP and DQ2 class II beads for each test (all R 2 > 0.99). As the monoclonal anti‐HLA class II antibody does not recognise all HLA specificities, all negative beads (DQ3, DQ4, DQ5 and DQ6 specificities) were removed for mean MFI calculation. The highest MFI measured on LS200 and FM3D for OLSAB2 were close (22,042 and 23,895 MFI respectively), as was the case for LS200 WLSA2 maximum MFI (22,376). WLSA2 gave a higher maximum MFI on FM3D (37,008). EC50 were similar between LS200 and FM3D for each supplier: 0.149 and 0.150 μg/mL with OLSAB1, 0.621 and 0.635 μg/mL with WLSA1 respectively. Friedman test (non‐parametric Anova comparison) illustrated that the four curves were significantly different ( p = 0.006). Post hoc analysis with Dunn's multiple comparisons test revealed the only statistically significant difference was between LS200 WLSA2 and FM3D OLSAB2 ( p = 0.003). Threshold recalculation (bottom of the Boltzmann sigmoid plus 2 or 3 s): 708 and 981 for LS200 OLSAB2, 858 and 1187 for FM3D OLSAB2, 480 and 665 for LS200 WLSA2, 603 and 830 for FM3D WLSA2.

Article Snippet: The new Luminex model FlexMap 3D is progressively replacing the previous Luminex generation in HLA laboratories for the detection and identification of anti‐HLA antibodies.

Techniques: Comparison, Bioprocessing, Incubation

Journal: Bioactive Materials

Article Title: Construction, evaluation, and applications of renal barrier-on-a-chip system

doi: 10.1016/j.bioactmat.2025.12.032

Figure Lengend Snippet: (A) Co-culturing hiPSC-derived tubular cells with immortalized cells in a flow-based OoC resulted in a 2-fold higher TEER compared to static co-cultures(a) Evaluation by the TEER evolution with culture time for the RPTEC-only and coculture tissue layers. (b) Time course of reported resistances of the RPTEC-only (blue circles), bilayer (red squares), and HUVEC-only (green triangles) tissue layers .(B) Microfluidic organ-on-a-chip device reconstitutes kidney glomerular capillary function in vitro. (a) Quantification of the glomerular filtration (urinary clearance) of albumin and inulin molecules that were continuously infused over 6 h into the capillary channel of the glomerulus chip that was lined by hiPS-cell-derived podocytes and human glomerular endothelial cells. (b) Filtration of albumin and inulin in control microfluidic chips without human kidney podocytes quantified over 6 h of continuous infusion using the methods described above. RPTECs, renal proximal tubular epithelial cells . (C) Cyclosporine and cisplatin toxicity are reversed by SGLT2 inhibition. (a) Schematic of glucose transport in proximal tubule cells and mechanism of nephroprotective effect of empagliflozin (gliflozin). (b) Fluorescent glucose analog and lipid accumulation in 3D cysts exposed to cyclosporine or cisplatin in the presence or absence of empagliflozin . (D) Reactive oxygen species production of glomerular cells after exposure to high glucose conditions at different concentrations . (E) Assessment of the filtration capacity of RPTEC tissue showing the effects of HUVECs and flow induced shear stress. (a) Transfer rates of the glucose probe, 2NBDG measured in static and perfused culture conditions. Both reabsorption (a → b) and reverse transfer rates (b → a) were quantified. (b) Fluorescent confocal z-stacked images of the RPTEC tissue layer in bilayer and single layer configurations. A considerably higher amount of BSA was precipitated in the basolateral milieu of RPTECs in the bilayer system indicating a higher intake of the substrate .

Article Snippet: , Enabled high-throughput screening of drug-transporter interactions in a 3D microfluidic tubule model. , Mimetas OrganoPlate platform (384-well format); collagen I gel channel. , Conditionally immortalized human proximal tubule cells (ciPTEC-OAT1) , Expressed OAT1, OCT2, P-gp, MRP2/4; validated P-gp substrate efflux function. , Early-stage drug transporter interaction screening; high-throughput toxicity assessment. , [ ] .

Techniques: Derivative Assay, In Vitro, Filtration, Control, Inhibition, Shear

Journal: Bioactive Materials

Article Title: Construction, evaluation, and applications of renal barrier-on-a-chip system

doi: 10.1016/j.bioactmat.2025.12.032

Figure Lengend Snippet: Representative Renal Barrier Chip Designs. (A) RGD peptide functionalization of PEEK surfaces via a polydopamine coating improves biocompatibility and cell response . (B) Functionalization of PETE membranes for the enhancement of cellular adhesion in Organ-on-a-Chip devices . (C) A novel microfluidic platform that combines two plasma surface treatments: PAC and APPJ, enable reagent-free covalent immobilization of biomolecules is described here . (D) Stiffness-tunable gelatin-mTG hydrogel provides an ideal platform to study kidney podocyte mechanotransduction . (E) the modified photolithography and micromolding process used to prepare the micro-hemispherical “bubble” topography for podocyte cultivation . (F) MDCK cells are seeded on a fibronectin reservoir in front of a PDMS block containing cylindrical microtubes of different sizes. The cells start crawling into the openings of the microtubes once they are in full confluenc . (G) Design of microfluidic Organ Chip device to recapitulate the structure and function of the kidney glomerular capillary wall . (H) Design of the biologically inspired microfluidic extruded topographic hollow fiber (h-FIBER), consisting of a vessel-like perfusable tubular channel and a glomerulus-like knot with microconvex topography on its surface . (I) Fabrication of 3D VasPT Models via Sacrificial Printing . (J) Formation of channels in the chip via pre-placed inner pins, which are removed after matrix solidification . (K) Multiphoton-guided creation of 3D cellularized microvessels . (L) Schematic of the construction steps of the glomerulus chip, where bundles of hollow fibers were spherically twisted and embedded in designed Bowman's capsules to form spherical glomerular capillary tufts .

Article Snippet: , Enabled high-throughput screening of drug-transporter interactions in a 3D microfluidic tubule model. , Mimetas OrganoPlate platform (384-well format); collagen I gel channel. , Conditionally immortalized human proximal tubule cells (ciPTEC-OAT1) , Expressed OAT1, OCT2, P-gp, MRP2/4; validated P-gp substrate efflux function. , Early-stage drug transporter interaction screening; high-throughput toxicity assessment. , [ ] .

Techniques: Clinical Proteomics, Modification, Blocking Assay, Capsules

Journal: Bioactive Materials

Article Title: Construction, evaluation, and applications of renal barrier-on-a-chip system

doi: 10.1016/j.bioactmat.2025.12.032

Figure Lengend Snippet: Evaluation and Validation of Renal Barrier Models. (A) High-resolution electron microscopy analysis of tissue-specific phenotypes in the engineered glomerulus biomimetic microfluidic device . Red arrows indicate podocyte foot processes and formation of interdigitation-like organization, green arrows indicate formation of secondary and tertiary foot processes, and orange arrows indicate formation of short protrusions around the SF nanofibers. (B) PTECs and GMECs seeded in 3D VasPT tissues exhibit healthy and mature phenotypes. TEM and SEM micrographs showing densely packed PTEC microvilli that are ∼1.2 μm in height . (C) The podocyte lines form a continuous layer, distinguishable from the human glomerular endothelial cells layer in Organoplate™ . (D) Developing kidney organoids cultured in vitro under high fluid flow exhibit enhanced vascularization during nephrogenesis .

Article Snippet: , Enabled high-throughput screening of drug-transporter interactions in a 3D microfluidic tubule model. , Mimetas OrganoPlate platform (384-well format); collagen I gel channel. , Conditionally immortalized human proximal tubule cells (ciPTEC-OAT1) , Expressed OAT1, OCT2, P-gp, MRP2/4; validated P-gp substrate efflux function. , Early-stage drug transporter interaction screening; high-throughput toxicity assessment. , [ ] .

Techniques: Biomarker Discovery, Electron Microscopy, Cell Culture, In Vitro

Journal: Bioactive Materials

Article Title: Construction, evaluation, and applications of renal barrier-on-a-chip system

doi: 10.1016/j.bioactmat.2025.12.032

Figure Lengend Snippet: Representative Renal Barrier Applications. (A)A disease model of diabetic nephropathy in a glomerulus-on-a-chip microdevice. (a) GFB filtration dysfunction under high glucose conditions (b) Visualized images of migrated glomerular cells along with the GFB on 3D basement membrane in dynamic culture under high glucose conditions. The podocyte processes were observed to protrude into the 3D Matrigel over time. The white arrows represent the podocyte processes . (B) Validation of the hAKPC-P GOAC system as a diagnostic and drug screening platform. (a) The GOAC was exposed to serum from patients with other kidney diseases (FSGS, AS, PKD) to assess albumin permeability. (b) The GOAC was treated with MN serum in the presence or absence of the therapeutic drug α-MSH, and its effect on albumin leakage was evaluated . (C) Drug-induced nephrotoxicity tests of glomerulus and proximal tubule MPS. (a) Dynamic cellular images at 7 days after exposure to nephrotoxins in Drug-induced nephrotoxicity tests. (b) Glucose clearance (mL min−1) across all drug conditions . (D) Measurement of oxygen consumption rates of human renal proximal tubule cells in an array of organ-on-chip devices to monitor drug-induced metabolic shifts. (a) Bottom view of the O-MCP with 96 devices and a zoomed-in image of a single device. (b) Cross-section side view of an O-MCP device. (c) The O-MCP and corresponding measurement technique allowed single devices to be measured repeatedly or multiple devices to be measured sequentially . (E)Validation of targeted inhibition of URAT1 transporter by kaempferide based on a kidneyon-a-chip. a) Design and structure of the microfluidic chip.; b) 3D structure drawing and binding site prediction of the docking model of kaemperide and URAT1 . (F)An implantable bioreactor for renal cell therapy. (a) Bioreactor design and constituent components. (b) Relative positional relationship between the blood flow pathway and the cell culture region. c) High cell viability on cell inserts after 3- and 7- day implants .

Article Snippet: , Enabled high-throughput screening of drug-transporter interactions in a 3D microfluidic tubule model. , Mimetas OrganoPlate platform (384-well format); collagen I gel channel. , Conditionally immortalized human proximal tubule cells (ciPTEC-OAT1) , Expressed OAT1, OCT2, P-gp, MRP2/4; validated P-gp substrate efflux function. , Early-stage drug transporter interaction screening; high-throughput toxicity assessment. , [ ] .

Techniques: Filtration, Membrane, Biomarker Discovery, Diagnostic Assay, Drug discovery, Permeability, Inhibition, Binding Assay, Cell Culture